GRAIL Q3 Earnings Ahead: Galleri Test Adoption to Drive Growth

GRAL's Q3 earnings should have benefited from rising Galleri test adoption, expanding digital health partnerships and growing clinical evidence of cancer detection.

Zacks Investment Research • 8 hours ago

Diamond Hill Small-Mid Cap Fund Q3 2026 Contributors And Detractors

The Fund declined 4.75% while the Russell 2500 Index declined 6.37%. Key contributors include Illumina, Revvity and Waystar. Key detractors include Regal Rexnord, Knife River and Red Rock Resorts.

Seeking Alpha • 17 hours ago

Will Revvity (RVTY) Beat Estimates Again in Its Next Earnings Report?

Revvity (RVTY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Investment Research • Oct 27, 2026

Revvity (RVTY) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Revvity (RVTY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research • Oct 27, 2026

ELV vs. RVTY: Which Stock Is the Better Value Option?

Investors looking for stocks in the Medical Services sector might want to consider either Elevance Health (ELV) or Revvity (RVTY). But which of these two stocks offers value investors a better bang for their buck right now?

Zacks Investment Research • Oct 23, 2026

Revvity Launches Signals LabGistics to Coordinate Scientific Workflows

RVTY's AI-first Signals LabGistics aims to streamline scientific workflows, enhance R&D-to-manufacturing coordination and expand software growth opportunities.

Zacks Investment Research • Oct 22, 2026

Revvity: A Diagnostics Annuity Is Quietly Funding An AI Data Engine

Revvity is transforming from a legacy tools company into a diagnostics-driven, AI-enabled platform with robust double-digit diagnostics growth. The Diagnostics segment organic revenue rose 11%, while software ARR grew in the mid-20% range, offsetting Life Sciences weakness and China exit headwinds. Operating leverage is strong, with 13% EPS growth on 3% organic revenue growth and free cash flow conversion exceeding 100%, supporting deleveraging and strategic reinvestment.

Seeking Alpha • Oct 22, 2026

Revvity Launches Signals LabGistics Solution to Connect and Orchestrate Scientific Workflows

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced that its Revvity Signals Software business is launching the Signals LabGistics™ solution, an AI-first, scientific workflow orchestration solution designed to connect and coordinate processes, workflows, and tasks from discovery to manufacturing. The Signals LabGistics offering uses AI-powered workflow design to translate natural-language descriptions and standard operating procedures into coordinated scientific workflows. As.

Business Wire • Oct 20, 2026

How to Invest in AI Drug Discovery

.Danaher (DHR), one of the world's largest providers of medical diagnostics and laboratory equipment, recently announced plans to launch its first AI-powered autonomous laboratory, scheduled to operate at commercial scale in early 2027. While market trading barely moved the stock on the announcement date, the news marks a quiet turning point for life science automation.

ETF Trends • Oct 14, 2026

Revvity to Present at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today announced it will present at the following investor conferences: 2026 Jefferies Global Healthcare Conference Tuesday, November 17, 2026 8:00 a.m. GMT – Prahlad Singh, president and chief executive officer 9th Annual Evercore Healthcare Conference Wednesday, December 2, 2026 9:10 a.m. ET – Prahlad Singh Attendees will receive an update on the Company and its strategic priorities during fireside chats. Live audio webcasts will be.

Business Wire • Oct 13, 2026